Canada Glioma therapeutics market size stood at around USD xx million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of X.X% during the forecast period.
The incidence of glioblastoma (GB), also known as Glioma, is 4 per 100,000 people in Canada, according to the Brain Tumour Registry of Canada. GB accounts for 12-15% of all intracranial tumours and 50-60% of astrocytic tumours. GBMs increase in frequency with age and affect more men than women. GBs may manifest at any age but primarily affect adults with a peak incidence between 45 and 75 years of age. Only 3% of childhood brain tumours are glioblastomas.The development of a promising drug to treat Glioma has proved difficult to date, with many promising candidates failing to achieve the desired test results in the past few years. However, technological advancements in the diagnosis of gliomas and analysis of its progression through various imaging modalities have improved survival rates, thereby giving an enhanced edge for rapid evaluation of the efficacy of several pipeline drugs.
Market Driving Factors:
The driving factors in the growth of the glioma therapeutics market include incurable status of the disease, increase in the aging population, and increasing prevalence of brain disorders. A person’s risk of developing Glioma depends on many factors, including age, genetics, and exposure to risk factors. Growth in the glioma therapeutics market can also be attributed to patient’s constant contact with radiation and carcinogens. Furthermore, the late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in the rising cost of the treatment.